Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.40 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.40 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6163456 | 0.85 | NOTUM (0.47) | LMNAKDM4EPLOD2PLOD3PLOD1 | |
| SCHEMBL27519236 | 0.84 | KAT6A (0.48) | KAT6ALMNAGPR119DGAT2KDM4E | |
| SCHEMBL5868921 | 0.82 | GPR119 (0.43) | LMNAGPR119PLOD2PLOD3PLOD1 | |
| SCHEMBL6607286 | 0.81 | LMNA (0.64) | KAT6ALMNADGAT2PLOD2PLOD3 | |
| SCHEMBL5868879 | 0.80 | L3MBTL1 (0.51) | LMNAGPR119PLOD2PLOD3PLOD1 | |
| SCHEMBL12883023 | 0.79 | LMNA (0.51) | KAT6ALMNADGAT2KDM4EPLOD2 | |
| SCHEMBL5868871 | 0.79 | CYP3A4 (0.40) | KDM4EPLOD2PLOD3PLOD1ALDH1A1 | |
| SCHEMBL5869107 | 0.79 | TP53 (0.40) | LMNAKDM4EPLOD2PLOD3PLOD1 | |
| SCHEMBL24247727 | 0.77 | KAT6A (0.49) | KAT6ALMNADGAT2PLOD2PLOD3 | |
| SCHEMBL12664126 | 0.77 | KAT6A (0.53) | KAT6ALMNAKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1268626-C | Dihydro-benzo(b)(1,4)diazepin-2-one derivatives as mglur2 antagonists I | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | CN | disclosed |
| CN-1264825-C | Dihydro-benzo [ b ] [1,4] diazepin * -2-one derivatives as mGluR2 antagonists II | HOFFMANN LA ROCHE (CH) | 2006-07-19 | — | — | CN | disclosed |
| EP-1379511-B1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | EP | disclosed |
| EP-1379522-B1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | HOFFMANN LA ROCHE (CH) | 2005-01-26 | — | — | EP | disclosed |
| CN-1535266-A | Dihydro-benzo [b][1,4] diazepin-2-one derivatives as mglur 2 antagonists II | - | 2004-10-06 | — | — | CN | disclosed |
| CN-1522252-A | Dihydro-benzo(b)(1,4)diazepin-2-one derivatives as mglur2 antagonists I | - | 2004-08-18 | — | — | CN | disclosed |
| EP-1379522-A1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| EP-1379511-A1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6548495-B2 | Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| US-6544985-B2 | For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits | HOFFMAN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
| WO-2002083652-A1 | DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083665-A1 | DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | KAT6A 3557/4885LMNA 2394/4885GPR119 1166/4885 |
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | BDKRB1, BDKRB2, GRIN1 | KAT6A 3330/4885LMNA 3113/4885GPR119 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.